Treatment of Aggressive Non-Hodgkin's Lymphoma in Adults--are We Doing Any Better?

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 1996 Dec 1

PMID 9152968

Authors

H Hagberg

E Kimby

Affiliations

Soon will be listed here.

Abstract

Great improvement in the treatment of patients with aggressive non-Hodgkin's lymphoma (NHL) has been obtained with the introduction of new combination chemotherapy regimens in the 1970s. The hope that there would be further improvement has waned during recent years due to the fact that some controlled studies did not reveal any better results using the new more intensive treatment regimens. This is the reason for the question: are we doing any better?

References

Aviles A, Delgado S, Ruiz H, De La Torre A, Guzman R, Talavera A . Treatment of non-Hodgkin's lymphoma of Waldeyer's ring: radiotherapy versus chemotherapy versus combined therapy. Eur J Cancer B Oral Oncol. 1996; 32B(1):19-23. DOI: 10.1016/0964-1955(95)00058-5. View

Boyd D, Coleman M, Papish S, TOPILOW A, Kopel S, Bernhardt B . COPBLAM III: infusional combination chemotherapy for diffuse large-cell lymphoma. J Clin Oncol. 1988; 6(3):425-33. DOI: 10.1200/JCO.1988.6.3.425. View

Velasquez W, McLaughlin P, Tucker S, Hagemeister F, SWAN F, Rodriguez M . ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994; 12(6):1169-76. DOI: 10.1200/JCO.1994.12.6.1169. View

Fisher R, Gaynor E, Dahlberg S, Oken M, Grogan T, Mize E . A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann Oncol. 1994; 5 Suppl 2:91-5. DOI: 10.1093/annonc/5.suppl_2.s91. View

Gordon L, Harrington D, Andersen J, Colgan J, Glick J, NEIMAN R . Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med. 1992; 327(19):1342-9. DOI: 10.1056/NEJM199211053271903. View

Connors J, Klimo P, Fairey R, Voss N . Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. Ann Intern Med. 1987; 107(1):25-30. DOI: 10.7326/0003-4819-107-1-25. View

Gerhartz H, Engelhard M, Meusers P, Brittinger G, Wilmanns W, Schlimok G . Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood. 1993; 82(8):2329-39. View

Philip T, Hartmann O, Biron P, Cahn J, Pein F, Bordigoni P . High-dose therapy and autologous bone marrow transplantation in partial remission after first-line induction therapy for diffuse non-Hodgkin's lymphoma. J Clin Oncol. 1988; 6(7):1118-24. DOI: 10.1200/JCO.1988.6.7.1118. View

Vitolo U, Cortellazzo S, Liberati A, Freilone R, Falda M, Bertini M . Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma. J Clin Oncol. 1997; 15(2):491-8. DOI: 10.1200/JCO.1997.15.2.491. View

10.

DEVITA V, Lippman M, Hubbard S, Ihde D, Rosenberg S . The effect of combined modality therapy on local control and survival. Int J Radiat Oncol Biol Phys. 1986; 12(4):487-501. DOI: 10.1016/0360-3016(86)90056-8. View

11.

. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993; 329(14):987-94. DOI: 10.1056/NEJM199309303291402. View

12.

Harris N, Jaffe E, STEIN H, Banks P, Chan J, Cleary M . A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994; 84(5):1361-92. View

13.

Fanin R, Silvestri F, Geromin A, Cerno M, Infanti L, Zaja F . Primary systemic CD30 (Ki-1)-positive anaplastic large cell lymphoma of the adult: sequential intensive treatment with the F-MACHOP regimen (+/- radiotherapy) and autologous bone marrow transplantation. Blood. 1996; 87(4):1243-8. View

14.

Martelli M, Vignetti M, Zinzani P, Gherlinzoni F, Meloni G, Fiacchini M . High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian.... J Clin Oncol. 1996; 14(2):534-42. DOI: 10.1200/JCO.1996.14.2.534. View

15.

Koppler H, Pfluger K, Eschenbach I, Pfab R, Birkmann J, Zeller W . Randomised comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non-Hodgkin's lymphomas: treatment results and prognostic factor analysis in a multi-centre trial. Ann Oncol. 1994; 5(1):49-55. DOI: 10.1093/oxfordjournals.annonc.a058690. View

16.

Pettengell R, Radford J, Morgenstern G, Scarffe J, Harris M, Woll P . Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma. J Clin Oncol. 1996; 14(2):586-92. DOI: 10.1200/JCO.1996.14.2.586. View

17.

Arriagada R, Cosset J, Le Chevalier T, TUBIANA M . The value of adjunctive radiotherapy when chemotherapy is the major curative method. Int J Radiat Oncol Biol Phys. 1990; 19(5):1279-84. DOI: 10.1016/0360-3016(90)90244-e. View

18.

Meyer R, Quirt I, Skillings J, Cripps M, Bramwell V, Weinerman B . Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma. N Engl J Med. 1993; 329(24):1770-6. DOI: 10.1056/NEJM199312093292404. View

19.

Coiffier B . What treatment for elderly patients with aggressive lymphoma?. Ann Oncol. 1994; 5(10):873-5. DOI: 10.1093/oxfordjournals.annonc.a058722. View

20.

Young W, Greco F, Greer J, Hainsworth J . Aggressive non-Hodgkin's lymphoma in the elderly: an effective, well-tolerated treatment regimen containing extended-schedule etoposide. J Natl Cancer Inst. 1994; 86(17):1346-7. DOI: 10.1093/jnci/86.17.1346. View